Clinical trials: Alzheimer Disease, Early Onset
Alzheimer Disease, Early Onset
The Resting-state EEG Gamma Oscillations in Alzheimer's Disease
The literature suggests a strong association between amyloid accumulation and gamma alterations, emerging gamma activity as a biomarker candidate for Alzheimer's pathology.
- Trial name
- EEG (NCT05989087)
- Testing
- CSF
- Where
- Turkey (Türkiye)
- Volunteers
- 51 people, healthy volunteers welcome
- Sponsor
- Görsev Yener, MD, PhD
Alzheimer Disease, Early Onset
Adapted Home-based Exercise Program "T&E" (Test-and-Exercise) in Persons With Alzheimer's Disease (HOPE Trial)
The aim of this exploratory pilot study is to assess the feasibility and effectiveness of the adapted T\&E home-based exercise program on the basic functional mobility and executive functions in persons with mild or probable…
- Trial name
- HOPE (NCT04916964)
- Testing
- Test and exercise home-based program
- Where
- Switzerland
- Volunteers
- 12 people
- Sponsor
- HES-SO Valais-Wallis
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Repurposing Nucleoside Reverse Transcriptase Inhibitors for Treatment of AD
This is a randomized, double-blind clinical trial of a daily oral dose of 200 mg emtricitabine vs. placebo in 35 participants with biomarker-confirmed MCI or mild to moderate dementia due to Alzheimer's disease.
- Conditions
- Alzheimer Disease, Early Onset, Mild Cognitive Impairment, Moderate Dementia
- Trial name
- LINE-AD (NCT04500847)
- Testing
- Emtriva Capsule
- Where
- 2 sites in United States
- Volunteers
- 35 people
- Sponsor
- Butler Hospital
Alzheimers Disease, Dementia
Dominantly Inherited Alzheimer Network Trial: An Opportunity to Prevent Dementia. A Study of Potential Disease Modifying Treatments in Individuals at Risk for or With a Type of Early Onset Alzheimer's Disease Caused by a Genetic Mutation. Master Protocol DIAN-TU-001
The purpose of this study is to assess the safety, tolerability, biomarker, cognitive and clinical efficacy of investigational products in participants with an Alzheimer's disease-causing mutation by determining if treatment with…
- Conditions
- Alzheimers Disease, Dementia, Alzheimers Disease, Familial
- Trial name
- DIAN-TU (NCT01760005)
- Testing
- Gantenerumab, Solanezumab, E2814
- Where
- 38 sites in United States, Argentina and 13 more
- Volunteers
- 490 people, healthy volunteers welcome
- Sponsor
- Washington University School of Medicine
Familial Dementia With Neuroserpin Inclusion Bodies, Nervous System Heredodegenerative Disorder
Clinical and Genetic Studies of Familial Presenile Dementia With Neuronal Inclusion Bodies
The purpose of this study is to learn more about the medical problems and the genetic factors involved in a recently defined form of inherited dementia called "familial dementia with neuroserpin inclusion bodies (FDNIB)."…
- Trial name
- NCT00006176
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- National Human Genome Research Institute (NHGRI)
Alzheimer Disease, Early Onset
The Ketogenic Diet for Alzheimer's Disease
The ketogenic diet (KD) is a metabolic shift, which stimulates the liver oxidation of fatty acids to produce ketone bodies. These ketone bodies represent an alternative fuel source for the brain.
- Trial name
- CETOMA (NCT04701957)
- Testing
- Ketogenic diet
- Where
- France
- Volunteers
- 17 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Alzheimer Disease, Early Onset
Pilot Study to Investigate the Safety and Feasibility of AntiRetroviral Therapy for Alzheimer's Disease
The objective of the study is to evaluate the ability of (-)-L-2',3'-dideoxy-3'-thiacytidine (3TC) to engage its intended target, penetrate the central nervous system (CNS), suppress neurodegeneration, and assess safety and…
- Trial name
- ART-AD (NCT04552795)
- Testing
- 3TC
- Where
- 3 sites in United States
- Volunteers
- 12 people
- Sponsor
- The University of Texas Health Science Center at San Antonio
Alzheimer Disease, Early Onset
A Study to Assess THN391 in Subjects With Alzheimer's Disease
This is a Phase 1b study to evaluate different doses of the drug and see whether a drug is safe and how it behaves in the body. THN391 has already been assessed in healthy people without Alzheimer's disease.
- Trial name
- NCT06814730
- Testing
- THN391
- Where
- 4 sites in Netherlands, United Kingdom
- Volunteers
- 19 people
- Sponsor
- Therini Bio, Inc.
Alzheimer Disease, Early Onset, Cognitive Impairment
Hyperspectral Retinal Observations for the Cross-sectional Detection of Alzheimer's Disease
Two devices will be tested in this research: 1. Mantis Photonics' hyperspectral camera for non-invasive retinal examination (i.e., a hardware medical device under investigation). 2.
- Conditions
- Alzheimer Disease, Early Onset, Cognitive Impairment, Cognitive Decline
- Trial name
- NCT05604183
- Testing
- non-invasive hyperspectral retinoscopy, blood sample, Test of cognitive ability on tablet computer with CoGNIT software
- Where
- 2 sites in Sweden
- Volunteers
- 80 people
- Sponsor
- Mantis Photonics AB
Alzheimer Disease, Early Onset
ScentAware and OCT in MCI vs HC
The goal of this clinical trial is to learn whether a new smell test works as well as the standard clinical smell test, if there is a link between sense of smell and variations in the retina, and if these results could be used as…
- Trial name
- NCT06377241
- Testing
- ScentAware, UPSIT
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- University of Wisconsin, Madison
Alzheimer Disease, Early Onset
Donepezil Versus Non-drug Treatment in Alzheimer's Disease.
Donepezil, as well as the other symptomatic drugs of Alzheimer's disease, is not any more reimbursed by the French healthcare system, due to a controversy about its efficiency.
- Trial name
- CHOLINE-2 (NCT04661280)
- Testing
- Donepezil
- Where
- France
- Volunteers
- 240 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Down Syndrome (Trisomy 21), Neuropsychology
Neuropsychological Evaluation in Intellectual Disability (ENDI)
The goal of this observational study is to evaluate the acceptability ofpatients with trisomy 21 (T21) to perform the full battery of ENDI neurospychological tests and each of the subsets.
- Conditions
- Down Syndrome (Trisomy 21), Neuropsychology, Cognitive Aging, Alzheimer Disease
- Trial name
- ENDI (NCT07047963)
- Testing
- ENDI (Neuropsychological Evaluation in Intellectual Disability)
- Where
- France
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- Central Hospital, Nancy, France
Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease
A Study of Donanemab, RG6289, or the Combination of Donanemab and RG6289 in Presenilin 1 (PSEN1) E280A Mutation Carriers for the Treatment of Autosomal-Dominant Alzheimer's Disease
The study will be conducted in 2 blinded parts (Part 1 and Part 2). In Part 1, study participants who are mutation carriers will receive active donanemab and non-mutation carriers will receive placebo-donanemab for up to 18…
- Conditions
- Autosomal Dominant Alzheimers Disease, Early Onset Alzheimer Disease, Alzheimers Disease
- Trial name
- NCT06996730
- Testing
- Donanemab, RG6289
- Where
- Colombia
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Banner Health
Alzheimer Disease, Alzheimer Disease, Early Onset
Study of ARO-MAPT-SC in Healthy Participants and Participants With Early Alzheimer's Disease
Study to evaluate the safety, tolerability, pharmacokinetics (PK), and pharmacodynamics of ARO-MAPT-SC compared to placebo in adult healthy volunteers and in participants with early Alzheimer's disease (AD), defined as mild…
- Trial name
- NCT07221344
- Testing
- ARO-MAPT-SC
- Where
- 4 sites in Canada, New Zealand
- Volunteers
- 112 people, healthy volunteers welcome
- Sponsor
- Arrowhead Pharmaceuticals
Alzheimer Disease, Early Onset, Mild Cognitive Impairment
Senolytic Therapy to Modulate the Progression of Alzheimer's Disease (SToMP-AD) Study
The objective of the study is to determine the safety, feasibility, and efficacy of senolytics in older adults with amnestic mild cognitive impairment (MCI) or early-stage AD (Clinical Dementia Rating (CDR)=0.5 or 1) who are tau…
- Trial name
- SToMP-AD (NCT04685590)
- Testing
- Dasatinib + Quercetin
- Where
- 5 sites in United States, Spain
- Volunteers
- 48 people
- Sponsor
- Washington University School of Medicine
Alzheimer Disease, Early Onset
The Effect of Black Mulberry (Morus Nigra) Consumption on Cognitive Functions
The study was conducted with 44 patients who were diagnosed with mild-to-moderate Alzheimer's Disease. Participants were divided into 2 groups intervention group and the control group.
- Trial name
- NCT05406648
- Testing
- Morus nigra concentrate
- Where
- Turkey (Türkiye)
- Volunteers
- 44 people
- Sponsor
- Hacettepe University
Alzheimer Disease, Early Onset, Lewy Body Disease
Patients With Alzheimer's Disease or Related Youth Disease
This study aims to determine factors related to diagnosis delay for patients with young onset dementia (first symptoms before 60 years old) who live in North of France.
- Conditions
- Alzheimer Disease, Early Onset, Lewy Body Disease, Frontotemporal Lobar Degeneration
- Trial name
- PARMAAJJ (NCT03508024)
- Where
- France
- Volunteers
- 220 people
- Sponsor
- University Hospital, Lille
Alzheimer Disease, Early Onset
Novel Dementia Biomarkers
The study will investigate structural and functional characteristics of the brain of dementia patients compared to healthy controls in order to get a better insight into importance of early biomarkers for the diagnosis of…
- Trial name
- NCT04427436
- Testing
- No Intervention
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- German Center for Neurodegenerative Diseases (DZNE)
Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia
Neuropsychological Profiles and Musical Engagement in Parkinson's and Alzheimer's Disease
The goal of this Multicenter observational pilot study is to Compare the specifics of musical engagement (behaviors related to music in everyday life) in subjects aged over 60 with Alzheimer s disease, Parkinson s disease and…
- Conditions
- Alzheimer Disease, Early Onset, Parkinsons Disease with Dementia, Non Pharmacological Intervention
- Trial name
- MUSENGAGE (NCT06688968)
- Testing
- neuropsychologist interview, questionnaire
- Where
- 3 sites in France
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- University Hospital, Montpellier
Alzheimer Disease, Early Onset
Neuronavigation-guided FUS-induced BBB Opening in Alzheimer's Disease Patients and Its Effects on Brain Amyloid and Tau
The primary purpose of this phase 1b study is to further assess the safety and reversibility of focused ultrasound induced blood-brain barrier opening (FUS-BBBO) in participants with Alzheimer´s Disease (AD) using a…
- Trial name
- FUS-AD (NCT06600880)
- Testing
- Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Columbia University